Recent trends in the epidemiology of invasive mycoses

Current Opinion in Infectious Diseases

Volumn 15, Issue 6, 2002, Pages 569-574

  Clark, Thomas A ^a   Hajjeh, Rana A ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Epidemiology; Mycoses; Prevention and control

Indexed keywords

ANTIFUNGAL AGENT; CORTICOSTEROID; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; POSACONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDIASIS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCOSIS; FUSARIUM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INTENSIVE CARE UNIT; MYCOSIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR; TUBERCULOSIS;

EID: 0036916341     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200212000-00003     Document Type: Review

References (52)

1. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002; 51:1-32. New consensus guidelines intended for health care practitioners. Reviews epidemiology of catheter-related BSIs and evaluates the evidence for specific recommendations.
2. Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. Clin Infect Dis 1999; 29:1164-1170.
3. Hajjeh R, Sofair A, Harrison L, et al. Fluconazole resistance among Candida bloodstream isolates: Incidence and correlation with outcome from a population-based study. In: Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America; 2001. Abstract 641, p. 148.
4. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000; 19:319-324.
5. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33:177-186.
6. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630. Contains the most recent data from the CDC National Nosocomial Infections Surveillance system. Provides more evidence for the possibility of emergence of antifungal-resistant organisms given the frequent use of fluconazole in ICUs.
7. Pfaller MA, Diekema DJ, Jones RN, et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002; 40:852-856. Important multinational sentinel surveillance for candida BSIs, including antifungal susceptibility testing of isolates. Notes the trend of decreasing antifungal susceptibility in organisms associated with increasing patient age.
8. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44:747-751.
9. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998; 36:1886-1889.
10. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31:327-332.
11. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998; 30:121-129.
12. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999; 35:19-25.
13. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50:56-65.
14. Slavin MA, Australian Mycology Interest Group. The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 2002; 49 (Suppl 1):3-6.
15. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-1466.
16. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917. Important paper from a large transplant center describing continued morbidity and mortality associated with Aspergillus, as well as the emergence of other invasive molds.
17. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-1324. Single-institution review of invasive mold infections, confirming high risk associated with period of GVHD.
18. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19:801-808.
19. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: Incidence and risk factors in 395 patients. Br J Haematol 2002; 116:475-482. Multi-center review from Spain of invasive fungal infections in recipients of HLA-identical sibling peripheral blood stem cell transplant.
20. Gordon SM, Avery RK. Aspergillosis in lung transplantation: Incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3:161-167. Clinically oriented review of aspergillosis among lung transplant recipients.
21. Singh N, Wagener MM, Marino IR, Gayowski T. Trends in invasive fungal infections in liver transplant recipients: Correlation with evolution in transplantation practices. Transplantation 2002; 73:63-67. Thorough single-institution case series and review of epidemiology of invasive fungal infections in relation to evolving liver transplantation technology.
22. Abbott KC, Hypolite I, Poropatich RK, et al. Hospitalizations for fungal infections after renal transplantation in the United States. Transpl Infect Dis 2001; 3:203-211.
23. Panackal A, Dahlman A, Keil K, et al. Outbreak of invasive aspergillosis among renal transplant recipients: Possible association with sirolimus combined with mycophenolate. In: Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America; 2001. Abstract 616, p. 144.
24. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-615.
25. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001; 32:358-366. Comprehensive, systematic review describing significant mortality related to aspergillus despite advances in diagnosis and treatment.
26. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
27. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30 (Suppl 1):S5-S14.
28. Haddad NE, Powderly WG. The changing face of mycoses in patients with HIV/AIDS. AIDS 2001; 11:365-368, 375-378.
29. Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-1998: Regional variation and temporal trends. Clin Infect Dis 2001; 32:955-962. Descriptive data from a large surveillance database in a developing country with a large AIDS epidemic. Describes the high morbidity associated with fungal opportunistic infections in Thailand.
30. Hien TV, Loc PP, Hoa NT, et al. First cases of disseminated penicilliosis marneffei infection among patients with acquired immunodeficiency syndrome in Vietnam. Clin Infect Dis 2001; 32:e78-e80.
31. Rosenthal E, Marty P, Ferrero C, et al. [Disseminated Penicillium marneffei infection suggesting visceral leishmaniasis in an HIV infected patient]. Presse Medicale 2000; 29:363-364.
32. Mohri S, Yoshikawa K, Sagara H, Nakajima H. A case of Penicillium marneffei infection in an AIDS patient: The first case in Japan. Japan J Med Mycol 2000; 41:23-26.
33. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001; 77:769-773.
34. Carm AR, Wang W. Clinical manifestations of AIDS with cryptococcal meningitis. Trop Doctor 2001; 31:221-222.
35. Archibald LK, McDonald LC, Rheanpumikankit S, et al. Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients >/=15 years old, Bangkok. J Infect Dis 1999; 180:87-92.
36. Gangaidzo IT, Hakim JG, Mielke J, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. Clin Infect Dis 1998; 26:284-289.
37. Pancharoen C, Chindamporn A, Thisyakorn U. Childhood cryptococcosis: An increasing problem in the era of AIDS. J Med Assoc Thailand 2001; 84 (Suppl 1):S86-S90.
38. Gumbo T, Kadzirange G, Mielke J, et al. Cryptococcus neoformans meningoencephalitis in African children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 2002; 21:54-56. Clinically oriented review of cryptococcal meningitis in children.
39. Saiman L, Ludington E, Dawson JD, et al. Risk factors for Candida species colonization of neonata intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119-1124. Another important paper from the NEMIS cohort, this is one of the few papers describing risk factors for colonization with Candida species among neonatal ICU patients.
40. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 2002; 35:53-61. Describes the emergence of infection-related morbidity associated with new and more powerful immunosuppressant medications.
41. Sobel JD, Rex JH. Invasive candidiasis: Turning risk into a practical prevention policy? Clin Infect Dis 2001; 33:187-190.
42. Alberti C, Bouakline A, Ribaud P, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect 2001; 48:198-206. Confirms the success of laminar air flow systems and HEPA filtration in reducing mold-associated morbidity.
43. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-851.
44. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: A prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-1552.
45. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR 2000; 49:1-125.
46. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548. Clinical trial demonstrating a 7% absolute reduction of risk of fungal infections among high-risk surgical patients, treating 15 patients to prevent one fungal infection.
47. Montesinos J, Sola C, Maroto P, et al. Fungal infections in patients with solid tumors treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Eur J Clin Microbiol Infect Dis 2001; 20:569-572. Historical trial of itraconazole chemoprophylaxis, concluding that it is not necessary in this low-risk population.
48. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1999; 28:250-255.
49. Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazote versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999; 105:901-911.
50. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, et al. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44:1887-1893.
51. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 34:277-284.
52. Scharfstein JA, Paltiel AD, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med Decis Making 1997; 17:373-381.